(TRAK) ReposiTrak - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7002153044

Stock: Compliance, Traceability, Supply-Chain, E-Commerce, Consulting

Total Rating 24

Risk 78

Buy Signal -1.16

Software - Application » Application Software
Age: 27.2y

Market Cap: 189m
Avg Trading Vol: 877K USD

ATR: 4.63%
Peers RS (IBD): 15.15

EPS (Earnings per Share)

EPS CAGR: -41.35%
EPS Trend: 13.3%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 8.79%
Rev. Trend: 98.3%

Last SUE: -0.04
Qual. Beats: 0

Dividends

Dividend Yield	0.47%
Yield on Cost 5y	1.09%
Yield CAGR 5y	0.00%
Payout Consistency	97.4%
Payout Ratio	27.3%

Risk 5d forecast
Volatility	37.9%
Relative Tail Risk	-4.19%

Reward TTM
Sharpe Ratio	-1.79
Alpha	-64.54

Character TTM
Beta	0.853
Beta Downside	0.386

Drawdowns 3y
Max DD	58.85%
CAGR/Max DD	0.32

Description: TRAK ReposiTrak December 29, 2025

ReposiTrak, Inc. (NASDAQ:TRAK) is a Utah-based SaaS provider that delivers a B2B e-commerce, compliance, traceability, and supply-chain-management platform to multi-store retailers, wholesalers, distributors, and their suppliers across North America. Its core modules include Compliance Management (mitigating regulatory, legal, and criminal risk), Traceability Network (capturing product-level data), and Supply Chain Solutions (orchestrating supplier interactions), supplemented by consulting services for grocery, convenience, and specialty retail sectors. The firm rebranded from Park City Group in December 2023 and maintains a strategic partnership with Upshop to extend grocery-traceability capabilities.

Industry context suggests strong tailwinds: the global supply-chain-traceability market is projected to grow at a CAGR of ~12% through 2028, driven by tighter food-safety regulations (e.g., FDA’s FSMA) and rising consumer demand for provenance data. ReposiTrak’s SaaS model typically yields annual recurring revenue (ARR) growth rates of 20-30% in comparable niche players, with churn rates under 5% considered healthy. Recent quarterly filings (Q2 2024) indicated a 15% YoY increase in subscription revenue, reflecting broader e-commerce expansion in the grocery sector, which has been growing at roughly 8% annually.

For a deeper quantitative assessment, you may find ValueRay’s platform useful.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income: 7.13m TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 0.66 > 1.0
NWC/Revenue: 124.9% < 20% (prev 123.0%; Δ 1.87% < -1%)
CFO/TA 0.15 > 3% & CFO 8.09m > Net Income 7.13m
Net Debt (-28.3m) to EBITDA (8.70m): -3.26 < 3
Current Ratio: 6.54 > 1.5 & < 3
Outstanding Shares: last quarter (19.1m) vs 12m ago 0.15% < -2%
Gross Margin: 84.11% > 18% (prev 0.80%; Δ 8331 % > 0.5%)
Asset Turnover: 42.87% > 50% (prev 39.81%; Δ 3.06% > 0%)
Interest Coverage Ratio: 154.8 > 6 (EBITDA TTM 8.70m / Interest Expense TTM 49.8k)

Altman Z'' 1.51

A: 0.52 (Total Current Assets 34.1m - Total Current Liabilities 5.21m) / Total Assets 55.6m
B: -0.21 (Retained Earnings -11.5m / Total Assets 55.6m)
C: 0.14 (EBIT TTM 7.71m / Avg Total Assets 54.0m)
D: -2.08 (Book Value of Equity -11.3m / Total Liabilities 5.44m)
Altman-Z'' Score: 1.51 = BB

Beneish M -3.02

DSRI: 1.04 (Receivables 4.58m/3.97m, Revenue 23.1m/20.8m)
GMI: 0.96 (GM 84.11% / 80.33%)
AQI: 0.93 (AQ_t 0.38 / AQ_t-1 0.41)
SGI: 1.11 (Revenue 23.1m / 20.8m)
TATA: -0.02 (NI 7.13m - CFO 8.09m) / TA 55.6m)
Beneish M-Score: -3.02 (Cap -4..+1) = AA

What is the price of TRAK shares?

As of February 10, 2026, the stock is trading at USD 10.44 with a total of 70,971 shares traded.
Over the past week, the price has changed by -4.22%, over one month by -9.92%, over three months by -30.29% and over the past year by -49.45%.

Is TRAK a buy, sell or hold?

ReposiTrak has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy TRAK.

StrongBuy: 0
Buy: 1
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the TRAK price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	29	177.8%
Analysts Target Price	29	177.8%
ValueRay Target Price	9.9	-5.6%

TRAK Fundamental Data Overview February 10, 2026

P/E Trailing = 28.7778
P/S = 8.1892
P/B = 3.7767
P/EG = 2.13
Revenue TTM = 23.1m USD
EBIT TTM = 7.71m USD
EBITDA TTM = 8.70m USD
Long Term Debt = 225.0k USD (from longTermDebt, last quarter)
Short Term Debt = 232.3k USD (from shortTermDebt, last quarter)
Debt = 457.3k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.3m USD (from netDebt column, last quarter)
Enterprise Value = 161.1m USD (189.5m + Debt 457.3k - CCE 28.8m)
Interest Coverage Ratio = 154.8 (Ebit TTM 7.71m / Interest Expense TTM 49.8k)
EV/FCF = 19.99x (Enterprise Value 161.1m / FCF TTM 8.06m)
FCF Yield = 5.00% (FCF TTM 8.06m / Enterprise Value 161.1m)
FCF Margin = 34.85% (FCF TTM 8.06m / Revenue TTM 23.1m)
Net Margin = 30.83% (Net Income TTM 7.13m / Revenue TTM 23.1m)
Gross Margin = 84.11% ((Revenue TTM 23.1m - Cost of Revenue TTM 3.68m) / Revenue TTM)
Gross Margin QoQ = 85.70% (prev 84.24%)
Tobins Q-Ratio = 2.90 (Enterprise Value 161.1m / Total Assets 55.6m)
Interest Expense / Debt = 2.48% (Interest Expense 11.3k / Debt 457.3k)
Taxrate = 19.83% (450.0k / 2.27m)
NOPAT = 6.18m (EBIT 7.71m * (1 - 19.83%))
Current Ratio = 6.54 (Total Current Assets 34.1m / Total Current Liabilities 5.21m)
Debt / Equity = 0.01 (Debt 457.3k / totalStockholderEquity, last quarter 50.2m)
Debt / EBITDA = -3.26 (Net Debt -28.3m / EBITDA 8.70m)
Debt / FCF = -3.51 (Net Debt -28.3m / FCF TTM 8.06m)
Total Stockholder Equity = 49.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.22% (Net Income 7.13m / Total Assets 55.6m)
RoE = 14.52% (Net Income TTM 7.13m / Total Stockholder Equity 49.1m)
RoCE = 15.62% (EBIT 7.71m / Capital Employed (Equity 49.1m + L.T.Debt 225.0k))
RoIC = 12.44% (NOPAT 6.18m / Invested Capital 49.7m)
WACC = 9.04% (E(189.5m)/V(189.9m) * Re(9.06%) + D(457.3k)/V(189.9m) * Rd(2.48%) * (1-Tc(0.20)))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.86%
[DCF Debug] Terminal Value 77.60% ; FCFF base≈7.73m ; Y1≈9.33m ; Y5≈15.1m
Fair Price DCF = 13.09 (EV 211.1m - Net Debt -28.3m = Equity 239.4m / Shares 18.3m; r=9.04% [WACC]; 5y FCF grow 22.00% → 2.90% )
EPS Correlation: 13.32 | EPS CAGR: -41.35% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.31 | Revenue CAGR: 8.79% | SUE: -0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-06-30): EPS=0.39 | Chg30d=-0.010 | Revisions Net=+1 | Growth EPS=+11.4% | Growth Revenue=+6.2%
EPS next Year (2027-06-30): EPS=0.51 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+30.8% | Growth Revenue=+24.2%

Additional Sources for TRAK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle